Literature DB >> 2424988

HLA-B27 antigenicity: antibodies against the chemically synthesized 63-84 peptide from HLA-B27.1 display alloantigenic specificity and discriminate among HLA-B27 subtypes.

S Rojo, J A López de Castro, P Aparicio, G Van Seventer, R Bragado.   

Abstract

A chemically synthesized peptide with an amino acid sequence identical to that of the segment spanning residue 63-84 of the major HLA-B27.1 subtype antigen has been obtained. Specific antibodies were raised in rabbits against this peptide, coupled to keyhole limpet hemocyanin carrier. These antibodies lysed lymphoblastoid cell lines expressing HLA-B27.1 in a complement-mediated cytotoxicity assay. They lysed neither B27-negative target cells, nor B27-positive cells expressing other B27 subtype antigens. Complement-mediated lysis of B27.1-positive targets was inhibited by free peptide and by peptide coupled to an unrelated carrier. In addition, the lytic action of the rabbit antiserum was blocked by a monoclonal antibody with no complement-activating capacity that under the conditions of the assay, was specific for HLA-B27. These results indicate that rabbit antibodies against the 63-84 peptide recognize the native HLA-B27.1 antigen; this antiserum is allospecific in character; and it discriminates among B27 subtypes. Thus the data provide direct evidence on the contribution of the hypervariable region spanning residues 63-84 to the alloantigenic specificity of HLA-B27.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424988

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Definition of epitopes on HLA class I molecules by polyclonal antipeptide sera.

Authors:  M Bouillot; J Choppin; J P Levy
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

2.  Analysis of the molecular mimicry between HLA-B27 and a bacterial OmpA protein using synthetic peptides.

Authors:  D T Yu; T Hamachi; M Hamachi; G Tribbick
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

3.  DNA sequence of HLA-A11: remarkable homology with HLA-A3 allows identification of residues involved in epitopes recognized by antibodies and T cells.

Authors:  E P Cowan; M L Jelachich; W E Biddison; J E Coligan
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

4.  A transposable epitope of HLA-B7, B40 molecules.

Authors:  J P Ways; D A Lawlor; A M Wan; P Parham
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

Review 5.  Acute anterior uveitis and HLA-B27.

Authors:  P J Derhaag; T E Feltkamp
Journal:  Int Ophthalmol       Date:  1990-01       Impact factor: 2.031

Review 6.  Functional sites of human class I MHC molecules: paradigms a dozen?

Authors:  P Parham
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

7.  Autoantibodies to the HLA-B27 sequence cross-react with the hypothetical peptide from the arthritis-associated Shigella plasmid.

Authors:  N Tsuchiya; G Husby; R C Williams; H Stieglitz; P E Lipsky; R D Inman
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

8.  Epitope mapping of an HLA-B27 monoclonal antibody that also reacts with a 35-kD bacterial outer-membrane protein.

Authors:  A Toubert; M Hamachi; C Raffoux; M S Park; D T Yu
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

9.  Antibody activity in ankylosing spondylitis sera to two sites on HLA B27.1 at the MHC groove region (within sequence 65-85), and to a Klebsiella pneumoniae nitrogenase reductase peptide (within sequence 181-199).

Authors:  C Ewing; R Ebringer; G Tribbick; H M Geysen
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

10.  Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease.

Authors:  P L Schwimmbeck; D T Yu; M B Oldstone
Journal:  J Exp Med       Date:  1987-07-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.